LAURA WHITED: Open Payments
NPI 1447871934 · KENSETT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 45 payments from 12 companies in 2025. Trend: 2023 $548 · 2024 $506 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $430 |
| Vanda Pharmaceuticals Inc. | 3 | $80 |
| Lundbeck LLC | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 2 | $57 |
| GlaxoSmithKline, LLC. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Verona Pharma, Inc. | 1 | $23 |
| Viatris Specialty LLC | 1 | $23 |
| Indivior Inc. | 1 | $22 |
Products named: VRAYLAR, HETLIOZ, REXULTI, BREZTRI, TRELEGY ELLIPTA, CAPLYTA, GVOKE HYPOPEN, Ohtuvayre.
Industry payments across AR — which companies pay providers there.
